BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38261568)

  • 1. ncRNAs-mediated TIMELESS overexpression in lung adenocarcinoma correlates with reduced tumor immune cell infiltration and poor prognosis.
    Gao X; Tang M; Tian S; Li J; Wei S; Hua S; Liu W
    PLoS One; 2024; 19(1):e0296829. PubMed ID: 38261568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noncoding RNAs-mediated overexpression of KIF14 is associated with tumor immune infiltration and unfavorable prognosis in lung adenocarcinoma.
    Wang H; Tang F; Tang P; Zhang L; Gan Q; Li Y
    Aging (Albany NY); 2022 Oct; 14(19):8013-8031. PubMed ID: 36227151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA-DPA1 overexpression inhibits cancer progression, reduces resistance to cisplatin, and correlates with increased immune infiltration in lung adenocarcinoma.
    Shi K; Li QY; Zhang YQ; Huang H; Ding DX; Luo WM; Zhang J; Guo Q
    Aging (Albany NY); 2023 Oct; 15(20):11067-11091. PubMed ID: 37899135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein phosphatase 1 regulatory subunit 3G (PPP1R3G) correlates with poor prognosis and immune infiltration in lung adenocarcinoma.
    Zhuo X; Chen L; Lai Z; Liu J; Li S; Hu A; Lin Y
    Bioengineered; 2021 Dec; 12(1):8336-8346. PubMed ID: 34592886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma.
    Guo L; Li X; Liu R; Chen Y; Ren C; Du S
    Cancer Med; 2020 Sep; 9(18):6694-6709. PubMed ID: 32700817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and validation of non-coding RNA-mediated high expression of IQGAP3 in poor prognosis of lung adenocarcinoma.
    Su Z; Wang Y; Cao J; Ma J; Wang G; Ren H; Zhang Y; Sheng K; Zhu X; Wang Y
    J Gene Med; 2024 Jan; 26(1):e3664. PubMed ID: 38282143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADAR1 is a prognostic biomarker and is correlated with immune infiltration in lung adenocarcinoma.
    Yang W; Chen K; Yu Q; Liao R; He H; Peng Y; Yang Z; Zhang X
    Cancer Med; 2023 Jul; 12(13):14820-14832. PubMed ID: 37162299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.
    Yu L; Cao S; Li J; Han B; Zhong H; Zhong R
    Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
    Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
    Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SNCA correlates with immune infiltration and serves as a prognostic biomarker in lung adenocarcinoma.
    Zhang X; Wu Z; Ma K
    BMC Cancer; 2022 Apr; 22(1):406. PubMed ID: 35421944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Expression of DLGAP5 Indicates Poor Prognosis and Immunotherapy in Lung Adenocarcinoma and Promotes Proliferation through Regulation of the Cell Cycle.
    Tang X; Zhou H; Liu Y
    Dis Markers; 2023; 2023():9292536. PubMed ID: 36712920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis and immunotherapy significances of a cancer-associated fibroblasts-related gene signature in lung adenocarcinoma.
    Luo Y; Zhang S; Xie H; Su Q; He S; Lei Z
    Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):51-61. PubMed ID: 38279482
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Liu L; Wang C; Li S; Qu Y; Xue P; Ma Z; Zhang X; Bai H; Wang J
    Front Immunol; 2021; 12():677169. PubMed ID: 34354701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer-testis antigen KK-LC-1 is a potential biomarker associated with immune cell infiltration in lung adenocarcinoma.
    Kang Y; Gan Y; Jiang Y; You J; Huang C; Chen Q; Xu X; Chen F; Chen L
    BMC Cancer; 2022 Jul; 22(1):834. PubMed ID: 35907786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma.
    Zhang W; Shang X; Liu N; Ma X; Yang R; Xia H; Zhang Y; Zheng Q; Wang X; Liu Y
    BMC Pulm Med; 2022 Dec; 22(1):483. PubMed ID: 36539782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive analysis the prognostic and immune characteristics of mitochondrial transport-related gene SFXN1 in lung adenocarcinoma.
    Liu W; Du Q; Mei T; Wang J; Huang D; Qin T
    BMC Cancer; 2024 Jan; 24(1):94. PubMed ID: 38233752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction and Validation of a Tumor Microenvironment-Based Scoring System to Evaluate Prognosis and Response to Immune Checkpoint Inhibitor Therapy in Lung Adenocarcinoma Patients.
    Huang P; Xu L; Jin M; Li L; Ke Y; Zhang M; Zhang K; Lu K; Huang G
    Genes (Basel); 2022 May; 13(6):. PubMed ID: 35741714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel lncRNA-miRNA-mRNA competing endogenous RNA regulatory network in lung adenocarcinoma and kidney renal papillary cell carcinoma.
    Zhou Q; Li D; Zheng H; He Z; Qian F; Wu X; Yin Z; Bao PT; Jin M
    Thorac Cancer; 2021 Oct; 12(19):2526-2536. PubMed ID: 34453499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
    Zuo S; Wei M; Wang S; Dong J; Wei J
    Front Immunol; 2020; 11():1218. PubMed ID: 32714316
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.